International Scholarly Research Notices

Clinical Study

Oxaliplatin and Bolus-Modulated 5-Fluorouracil as a Second-Line Treatment for Advanced Pancreatic Cancer: Can Bolus Regimens Replace FOLFOX When Considered for Second Line?

Table 3

Summarizing efficacy results of the 2 regimens.
 FLOX arm3-week arm value
Partial responses3 (12.5%) 2 (16%) .23
Stable disease5 (21%) 5 (21%) .5
Clinical benefit3/8 (37.5%) 4/8 (50%) .19